NCT04653246 - Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone in NDMM | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 13, 2021

Primary Completion Date

September 15, 2025

Study Completion Date

January 13, 2029

Conditions

Multiple MyelomaNewly Diagnosed Multiple Myeloma (NDMM)Autologous Stem Cell Transplant

Interventions

DRUG

Isatuximab

Via IV at predetermined dosage and predetermined days during each cycle

DRUG

Lenalidomide

Oral, predetermined dosage and predetermined days during each cycle

DRUG

Bortezomib Injection

SQ Oral, predetermined dosage and predetermined days during each cycle

DRUG

Dexamethasone

IV or Oral predetermined dosage and predetermined days during each cycle

Trial Locations (1)

RECRUITING

Dana Farber Cancer Institute, Boston